[1]王群,林文华.伊伐布雷定治疗慢性心力衰竭的效果[J].青岛大学学报(医学版),2017,53(06):664-667.[doi:10.13361/j.qdyxy.201706009]
 WANG Qun,LIN Wenhua.CLINICAL EFFECT OF IVABRADINE IN TREATMENT OF PATIENTS WITH CHRONIC HEART FAILURE[J].JOURNAL OF QINGDAO UNIVERSITY (MEDICAL SCIENCES),2017,53(06):664-667.[doi:10.13361/j.qdyxy.201706009]
点击复制

伊伐布雷定治疗慢性心力衰竭的效果()
分享到:

《青岛大学学报(医学版)》[ISSN:2096-5532/CN:37-1217/R]

卷:
第53卷
期数:
2017年06期
页码:
664-667
栏目:
出版日期:
2018-03-21

文章信息/Info

Title:
CLINICAL EFFECT OF IVABRADINE IN TREATMENT OF PATIENTS WITH CHRONIC HEART FAILURE
文章编号:
1672-4488(2017)06-0664-04
作者:
王群林文华
泰达国际心血管病医院心内一科,天津 300457
Author(s):
WANG Qun LIN Wenhua
TEDA International Cardiovascular Hospital, Tianjin 300457, China
关键词:
伊伐布雷定心力衰竭心率治疗结果
Keywords:
ivabradine heart failure heart rate treatment outcome
分类号:
R541.61
DOI:
10.13361/j.qdyxy.201706009
文献标志码:
A
摘要:
目的 探讨伊伐布雷定治疗慢性心力衰竭的临床效果及其安全性。
方法 基础心率>70 min-1的慢性心力衰竭病人120例,随机分为伊伐布雷定组(治疗组)和常规治疗组(对照组),各60例。对照组给予常规治疗,包括应用血管紧张素转换酶抑制剂(ACEI)、β受体阻滞剂、硝酸酯类、利尿剂等;治疗组在常规治疗的基础上加用伊伐布雷定。两组分别于用药前及治疗3个月时进行24 h动态心电监护,随访至6个月,观察两组随访期间心力衰竭再入院、心血管死亡、症状心动过缓发生率。
结果 治疗3个月时,治疗组静息心率、24 h平均心率均较对照组明显降低,差异有显著性(t=4.92、4.83,P<0.01);心率30~40 min-1不良事件发生率治疗组较对照组增加,但差异无显著性(P>0.05),两组均无心率<30 min-1事件发生;治疗组1例病人RR间期>2.5 s,对照组未发生,两组均无>3 s的R-R间期出现;两组室性心动过速、室上性心动过速发生率比较差异无显著性(P>0.05)。6个月内治疗组心力衰竭再入院率较对照组下降,差异有显著性(χ2=4.23,P<0.05);两组心血管死亡、症状心动过缓发生率比较差异无统计学意义(P>0.05)。
结论 伊伐布雷定可显著降低慢性心力衰竭病人心率及心力衰竭再入院的发生率,且安全性良好。
Abstract:
Objective  To investigate the clinical effect and safety of ivabradine in the treatment of patients with chronic heart failure.
Methods  A total of 120 patients with chronic heart failure (basal heart rate ≥70 min-1) were randomly divided into ivabradine group (treatment group) and conventional treatment group (control group), with 60 patients in each group. The patients in the control group were given conventional treatment, including angiotensin-converting enzyme inhibitor, β-receptor blocker, nitrate, and diuretic, and those in the treatment group were given ivabradine in addition to the conventional treatment. All patients received 24 h dynamic ECG monitoring before treatment and at month 3 of treatment and were followed to month 6 of treatment. The two groups were observed with respect to the number of patients with readmission due to heart failure, cardiac death, or bradycardia.
Results  At month 3 of treatment, the treatment group had significantly lower resting heart rate and 24 h average heart rate than the control group (t=4.92 and 4.83,P<0.01). The treatment group had no significant increase in the incidence rate of heart rate 30-40 min-1 compared with the control group (P>0.05), and no patient experienced the adverse event of heart rate <30 min-1. One patient in the treatment group experienced an R-R interval of >2.5 s, which was not observed in the control group, and no patient experienced an R-R interval of >3 s. There were no significant differences in the incidence rates of ventricular tachycardia and supraventricular tachycardia between the two groups (P>0.05). At month 6 of treatment, the treatment group had a significant reduction in the readmission rate due to heart rate compared with the control group (χ2=4.23,P<0.05), and there were no significant differences in the incidence rates of cardiovascular death and bradycardia between the two groups.
Conclusion  Ivabradine can significantly reduce heart rate and readmission rate due to heart failure in patients with chronic heart failure and has good safety.
更新日期/Last Update: 2018-03-24